INM — InMed Pharmaceuticals Income Statement
0.000.00%
- $2.22m
- -$5.42m
- $4.14m
- 30
- 76
- 21
- 37
Annual income statement for InMed Pharmaceuticals, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2019 June 30th | R2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | USG | USG | USG | USG |
Status: | fx Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 1.09 | 4.14 |
Cost of Revenue | |||||
Gross Profit | — | — | — | 0.544 | 1.4 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 10.3 | 9.15 | 9.94 | 18.4 | 12.5 |
Operating Profit | -10.3 | -9.15 | -9.94 | -17.3 | -8.38 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -10 | -8.94 | -10.2 | -18.6 | -7.93 |
Provision for Income Taxes | |||||
Net Income After Taxes | -10 | -8.94 | -10.2 | -18.6 | -7.95 |
Net Income Before Extraordinary Items | |||||
Net Income | -10 | -8.94 | -10.2 | -18.6 | -7.95 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -10 | -8.94 | -10.2 | -18.6 | -7.95 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -48.2 | -42.8 | -38 | -26.6 | -3.25 |